In a trial matching new treatments to cancer patients based on the genetic makeup of their tumors, the tumors shrank in 22% of the patients treated with the AKT inhibitor drug ipatasertib. This included patients with breast cancer and endometrial cancer as well as two rarer forms—anal and salivary gland. In the…
in Health
AKT inhibitor shows signs of effectiveness in a patient trial matching drugs to tumor gene mutations
